Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting.
Viola D, Dona A, Caserta E, Troadec E, Besi F, McDonald T, Ghoda L, Gunes EG, Sanchez JF, Khalife J, Martella M, Karanes C, Htut M, Wang X, Rosenzweig M, Chowdhury A, Sborov D, Miles RR, Yazaki PJ, Ebner T, Hofmeister CC, Forman SJ, Rosen ST, Marcucci G, Shively J, Keats JJ, Krishnan A, Pichiorri F.
Viola D, et al. Among authors: rosenzweig m.
Leukemia. 2021 Jan;35(1):189-200. doi: 10.1038/s41375-020-0810-4. Epub 2020 Apr 16.
Leukemia. 2021.
PMID: 32296125
Free PMC article.